📊 CRDF Key Takeaways
Is Cardiff Oncology, Inc. (CRDF) a Good Investment?
Cardiff Oncology is a pre-revenue biotech company with virtually no commercial traction ($41K quarterly revenue) and severe cash burn ($12.3M annually) against a limited cash position of $8.5M, implying less than 1 year of runway at current burn rate. Despite a debt-free balance sheet and strong liquidity ratios, the company faces imminent funding requirements or operational restructuring, creating significant dilution risk to shareholders.
Cardiff Oncology’s fundamentals remain very weak: revenue is minimal and declining, while operating and free cash flow losses are extremely large relative to its asset and equity base. The balance sheet has no long-term debt and acceptable near-term liquidity, but the current cash position appears insufficient against the company’s annual cash burn, making future dilution or external financing a central risk.
Cardiff Oncology, Inc. Key Strengths (CRDF)
- Zero long-term debt and no leverage provides balance sheet flexibility
- Strong liquidity position with 3.27x current/quick ratios provides near-term operational cushion
- Positive stockholders' equity of $34.7M provides shareholder protection relative to liabilities
- Minimal capital expenditure requirements suggest asset-light development model
- Debt-free balance sheet with no long-term debt
- Current and quick ratios of 3.67x support near-term obligations
- Net loss was roughly flat year over year and diluted EPS improved year over year
CRDF Stock Risks: Cardiff Oncology, Inc. Investment Risks
- Critically low cash runway of approximately 8 months at current $12.3M annual operating burn rate
- Virtually non-existent revenue generation ($41K annually) indicates zero commercial viability
- Declining revenue trajectory (-13.2% YoY) suggests worsening commercial position
- Imminent capital raise needed will likely result in significant shareholder dilution
- Binary outcome inherent to preclinical/clinical stage biotech with no validated pipeline asset generating revenue
- Operating losses of $12.3M against minimal asset base unsustainable without external funding
- Operating income of -$48.96M and free cash flow of -$37.97M indicate an unsustainable business model without new funding
- Cash and equivalents of $17.47M are low relative to operating cash burn of $37.92M
- Revenue fell 13.2% year over year and remains too small to support operations
Key Metrics to Watch
- Cash runway and quarterly burn rate trends
- Pipeline milestone achievement and clinical trial progress
- Capital raise activity and terms (dilution percentage)
- Revenue inflection and partnership/licensing deals
- Cash runway relative to quarterly operating cash burn
- Progress in revenue generation and reduction in operating loss
Cardiff Oncology, Inc. (CRDF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.27x current ratio provides a solid financial cushion.
CRDF Profit Margin, ROE & Profitability Analysis
CRDF vs Healthcare Sector: How Cardiff Oncology, Inc. Compares
How Cardiff Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cardiff Oncology, Inc. Stock Overvalued? CRDF Valuation Analysis 2026
Based on fundamental analysis, Cardiff Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cardiff Oncology, Inc. Balance Sheet: CRDF Debt, Cash & Liquidity
CRDF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cardiff Oncology, Inc.'s revenue has grown significantly by 87% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.95 indicates the company is currently unprofitable.
CRDF Revenue Growth, EPS Growth & YoY Performance
CRDF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $41.0K | -$12.3M | $-0.18 |
| Q3 2025 | $120.0K | -$10.0M | $-0.17 |
| Q2 2025 | $121.0K | -$10.0M | $-0.21 |
| Q1 2025 | $109.0K | -$10.0M | $-0.20 |
| Q3 2024 | $141.0K | -$9.7M | $-0.22 |
| Q2 2024 | $108.0K | -$10.0M | $-0.25 |
| Q1 2024 | $83.0K | -$10.0M | $-0.22 |
| Q3 2023 | $93.0K | -$8.6M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cardiff Oncology, Inc. Dividends, Buybacks & Capital Allocation
CRDF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cardiff Oncology, Inc. (CIK: 0001213037)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRDF
What is the AI rating for CRDF?
Cardiff Oncology, Inc. (CRDF) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRDF's key strengths?
Claude: Zero long-term debt and no leverage provides balance sheet flexibility. Strong liquidity position with 3.27x current/quick ratios provides near-term operational cushion. ChatGPT: Debt-free balance sheet with no long-term debt. Current and quick ratios of 3.67x support near-term obligations.
What are the risks of investing in CRDF?
Claude: Critically low cash runway of approximately 8 months at current $12.3M annual operating burn rate. Virtually non-existent revenue generation ($41K annually) indicates zero commercial viability. ChatGPT: Operating income of -$48.96M and free cash flow of -$37.97M indicate an unsustainable business model without new funding. Cash and equivalents of $17.47M are low relative to operating cash burn of $37.92M.
What is CRDF's revenue and growth?
Cardiff Oncology, Inc. reported revenue of $41.0K.
Does CRDF pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
Where can I find CRDF SEC filings?
Official SEC filings for Cardiff Oncology, Inc. (CIK: 0001213037) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRDF's EPS?
Cardiff Oncology, Inc. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CRDF's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cardiff Oncology, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CRDF stock overvalued or undervalued?
Valuation metrics for CRDF: ROE of -35.6% (sector avg: 15%), net margin of -30,109.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CRDF's AI grade for 2026?
Our dual AI analysis gives Cardiff Oncology, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRDF's free cash flow?
Cardiff Oncology, Inc.'s operating cash flow is $-12.3M, with capital expenditures of $44.0K. FCF margin is -30,078.0%.
How does CRDF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -30,109.8% (avg: 12%), ROE -35.6% (avg: 15%), current ratio 3.27 (avg: 2).